Background: The aim of the Endocardial T-Wave Alternans Study was to prospectively assess the presence of T-wave alternans (TWA) or beat-to-beat repolarization changes on implantable cardioverter-defibrillator (ICD)-stored electrograms (EGMs) immediately preceding the onset of spontaneous ventricular tachycardia (VT) or fibrillation (VF).

Methods: Thirty-seven VT/VF episodes were compared to 116 baseline reference EGMs from the same 57 patients. A Bayesian model was used to estimate the T-wave waveform in each cardiac beat and a set of 10 parameters was selected to segment each detected T wave. Beat-by-beat differences in each T-wave parameter were computed using the absolute value of the difference between each beat and the following one. Fisher criterion was used for determining the most discriminant T-wave parameters, then top-M ranked parameters yielding a normalized cumulative Fisher score > 95% were selected, and analysis was applied on these selected parameters. Simulated TWA EGMs were used to validate the algorithm.

Results: In the simulation study, TWA was detectable even in the case of the smallest simulated alternans of 25 μV. In 13 of the 37 episodes (35%) occurring in nine of 16 patients, significant larger beat-to-beat variations before arrhythmia onset were detected compared to their respective references (median one positive episode per patient). Parameters including the T-wave apex amplitude seem the more discriminant parameters.

Conclusions: Detection of beat-by-beat repolarization variations in ICD-stored EGMs is feasible in a significant subset of cases and may be used for predicting the onset of ventricular arrhythmias.

Download full-text PDF

Source
http://dx.doi.org/10.1111/pace.12453DOI Listing

Publication Analysis

Top Keywords

t-wave alternans
12
ventricular arrhythmias
8
endocardial t-wave
8
alternans study
8
t-wave
7
parameters
5
detection t-wave
4
t-wave beat-by-beat
4
beat-by-beat variations
4
variations prior
4

Similar Publications

Objective: Treating iron deficiency (ID) with ferric carboxymaltose (FCM) in patients with heart failure with reduced ejection fraction (HFrEF) enhances morbidity, quality of life (QoL), and exercise capacity.

Methods: In the presented single-center, prospective follow-up study, symptomatic patients with HFrEF with ID and CIEDs scheduled for IV FCM were followed up for 12-months. Arrhythmic activity was evaluated from CIEDs and non-invasive markers from Holter recordings before and after FCM.

View Article and Find Full Text PDF

Background: Amiodarone and dronedarone are both class III antiarrhythmic medications used to treat arrhythmias. The objective of this study was to enhance the current understanding of adverse drug reaction (ADR) associated with amiodarone and dronedarone by employing data mining methods on the U.S.

View Article and Find Full Text PDF

A 58-year-old man presented with worsening dyspnea. Electrocardiogram showed variation in T-wave amplitude occurring every other beat. Transthoracic echocardiography revealed a severe aortic stenosis with beat-to-beat variation in stroke volume, suggestive of pulsus alternans.

View Article and Find Full Text PDF
Article Synopsis
  • - The K-REDEFINE study examined Heart Rate Turbulence (HRT) and T-wave alternans (TWA) as potential markers for predicting serious heart conditions in South Korean patients with acute myocardial infarction (MI) or heart failure (HF).
  • - The results showed that abnormal HRT was a strong predictor of adverse cardiac events, including cardiac death and hospitalizations due to heart failure, with a particularly high predictive value when combined with a reduced ejection fraction.
  • - In contrast, abnormal TWA was only associated with the overall risk of cardiac events and did not show as strong a predictive capability as HRT in this study.
View Article and Find Full Text PDF

Recurrent ventricular arrhythmias and heart failure induced by osimertinib- a case report.

Front Cardiovasc Med

August 2024

Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.

Article Synopsis
  • Osimertinib is a treatment for non-small cell lung cancer with EGFR mutations but poses risks of QT prolongation and heart failure, leading to rare but serious cardiac issues like ventricular fibrillation and Torsade de Pointes (TdP).
  • A 70-year-old woman experienced chest tightness and ventricular fibrillation after three months of osimertinib treatment, revealing severe QT prolongation and heart failure, requiring intensive management.
  • The case highlights the need for regular cardiac monitoring in patients taking osimertinib to prevent severe arrhythmias and manage potential heart complications effectively.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!